RecruitingNCT04233788

Metabolic Characterization of Space Occupying Lesions of the Brain

Metabolic Characterization of Space Occupying Lesions of the Brain Using in Vivo MR- (Spectroscopic) Imaging at 3 Tesla and 7 Tesla

Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

55 participants

Start Date

Sep 1, 2021

Study Type

OBSERVATIONAL

Conditions

Brain Tumor Glioma IDH Mutation

Summary

High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor type which is most often diagnosed in humans. Patients with IDH-mutated gliomas have a much longer survival time that IDH-wildtype. In IDH-mutated gliomas the substance 2-hydroxy-glutarate (2HG) is found, whereas in IDH-wildtype gliomas it is not. The underlying trial aims to measure 2HG directly with different MRSI sequences at 3 Tesla (3T) and 7 Tesla (7T) magnetic field strength. Apart from MRSI-techniques for IDH-typing it has been shown that CEST-imaging can also be performed to determine the IDH-status of gliomas. A total of 75 patients and 50 healthy controls will be examined in this study to evaluate the most accurate method for pre-operative IDH-status determination.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using specialized MRI brain scans to better identify and characterize brain tumors or masses. The goal is to find imaging markers that help doctors tell the difference between cancerous and non-cancerous brain lesions without surgery. **You may be eligible if...** - You are 18 or older - You are healthy and able to lie still in an MRI scanner for about one hour, OR - You have a suspected mass or lesion in the brain and need an MRI - You are able and willing to provide written informed consent **You may NOT be eligible if...** - You have a history of a brain cancer or neurodegenerative disease - You have an active implanted device such as a pacemaker or nerve stimulator - You are pregnant - You have tattoos on your head or neck area (which may cause safety issues in the MRI) - You are an emergency patient - You are mentally unable to choose to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)

The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.

Locations(1)

Institute for Diagnostic and Interventional Neuroradiology, University Hospital Bern

Bern, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04233788

Related Trials

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT055881411 location

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT073265664 locations

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT074649253 locations

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

NCT055555501 location

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT072106321 location